



175 Portland St, 4<sup>th</sup> Floor  
Boston, MA 02116  
+1 (617) 622-4003  
zafgen.com

21 March 2016

Protocol:	Title	EudraCT #
ZAF-312	A randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-Related Behaviour, Total Body Weight, and Safety Over 52 Weeks	<b>2015-000660-33</b>

RE: ZAF-312 Study Status

Dear Sir or Madam,

The purpose of this communication is to inform the Competent Authorities and Ethical Committees of the decision to close clinical trial ZAF-312, effective 21 Mar 2016. As we continue to evaluate beloranib's potential relationship to the occurrence of venous thromboembolism events, it has become clear that the next planned beloranib clinical trial protocol under discussion in patients with Prader-Willi syndrome will be different enough in design and scope that it is no longer appropriate to hold ZAF-312 open as an active clinical study protocol. Please note that no sites were opened and that no patients were enrolled or treated under the ZAF-312 study.

If you have any questions regarding this letter please do not hesitate to contact me.

Sincerely,

Kevin P. Malobisky, Ph.D., M.S., RAC  
Global Head of Regulatory and Quality  
Email: [kmalobisky@zafgen.com](mailto:kmalobisky@zafgen.com)  
Office: +1 (617) 648-4476